308 related articles for article (PubMed ID: 36768211)
1. MiRNA Differences Related to Treatment-Resistant Schizophrenia.
Pérez-Rodríguez D; Penedo MA; Rivera-Baltanás T; Peña-Centeno T; Burkhardt S; Fischer A; Prieto-González JM; Olivares JM; López-Fernández H; Agís-Balboa RC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768211
[TBL] [Abstract][Full Text] [Related]
2. Accessing Gene Expression in Treatment-Resistant Schizophrenia.
Moretti PN; Ota VK; Gouvea ES; Pedrini M; Santoro ML; Talarico F; Spindola LM; Carvalho CM; Noto C; Xavier G; Brietzke E; Gadelha A; Bressan R; Mari J; Belangero S
Mol Neurobiol; 2018 Aug; 55(8):7000-7008. PubMed ID: 29374346
[TBL] [Abstract][Full Text] [Related]
3. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
de Bartolomeis A; Prinzivalli E; Callovini G; D'Ambrosio L; Altavilla B; Avagliano C; Iasevoli F
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():356-366. PubMed ID: 28887181
[TBL] [Abstract][Full Text] [Related]
4. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia.
Kane JM; Agid O; Baldwin ML; Howes O; Lindenmayer JP; Marder S; Olfson M; Potkin SG; Correll CU
J Clin Psychiatry; 2019 Mar; 80(2):. PubMed ID: 30840788
[TBL] [Abstract][Full Text] [Related]
5. Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
O'Connell KS; Koch E; Lenk HÇ; Akkouh IA; Hindley G; Jaholkowski P; Smith RL; Holen B; Shadrin AA; Frei O; Smeland OB; Steen NE; Dale AM; Molden E; Djurovic S; Andreassen OA
Psychiatry Res; 2023 Jul; 325():115217. PubMed ID: 37146461
[TBL] [Abstract][Full Text] [Related]
6. Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects.
Boydstun C; Lynch S; DiGenova P
Int Clin Psychopharmacol; 2023 Sep; 38(5):361-366. PubMed ID: 37351582
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.
Iasevoli F; D'Ambrosio L; Notar Francesco D; Razzino E; Buonaguro EF; Giordano S; Patterson TL; de Bartolomeis A
Schizophr Res; 2018 Dec; 202():217-225. PubMed ID: 29934250
[TBL] [Abstract][Full Text] [Related]
8. miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia.
Sun J; Zhang X; Cong Q; Chen D; Yi Z; Huang H; Wang C; Li M; Zeng R; Liu Y; Huai C; Chen L; Liu C; Zhang Y; Xu Y; Fan L; Wang G; Song C; Wei M; Du H; Zhu J; He L; Qin S
Biol Psychiatry; 2022 Sep; 92(5):419-433. PubMed ID: 35662508
[TBL] [Abstract][Full Text] [Related]
9. Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.
Barone A; De Prisco M; Altavilla B; Avagliano C; Balletta R; Buonaguro EF; Ciccarelli M; D'Ambrosio L; Giordano S; Latte G; Matrone M; Milandri F; Francesco DN; Vellucci L; de Bartolomeis A
J Psychiatr Res; 2022 Nov; 155():572-578. PubMed ID: 36206601
[TBL] [Abstract][Full Text] [Related]
10. Investigating aberrantly expressed microRNAs in peripheral blood mononuclear cells from patients with treatment‑resistant schizophrenia using miRNA sequencing and integrated bioinformatics.
You X; Zhang Y; Long Q; Liu Z; Ma X; Lu Z; Yang W; Feng Z; Zhang W; Teng Z; Zeng Y
Mol Med Rep; 2020 Nov; 22(5):4340-4350. PubMed ID: 33000265
[TBL] [Abstract][Full Text] [Related]
11. The Promise of Predictive Biomarkers for Antipsychotic Efficacy: A Review of Peripheral microRNAs to Evaluate Schizophrenia Treatment Response.
Vadukapuram R; Trivedi C; Shah K; Mansuri Z; Reddy A
Prim Care Companion CNS Disord; 2022 Apr; 24(2):. PubMed ID: 35395147
[TBL] [Abstract][Full Text] [Related]
12. Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia.
Talarico F; Costa GO; Ota VK; Santoro ML; Noto C; Gadelha A; Bressan R; Azevedo H; Belangero SI
Mol Neurobiol; 2022 May; 59(5):3170-3182. PubMed ID: 35278208
[TBL] [Abstract][Full Text] [Related]
13. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.
Correll CU; Brevig T; Brain C
BMC Psychiatry; 2019 Nov; 19(1):362. PubMed ID: 31727015
[TBL] [Abstract][Full Text] [Related]
14. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.
Nakajima S; Takeuchi H; Plitman E; Fervaha G; Gerretsen P; Caravaggio F; Chung JK; Iwata Y; Remington G; Graff-Guerrero A
Schizophr Res; 2015 May; 164(1-3):164-75. PubMed ID: 25684554
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation signature aberration as potential biomarkers in treatment-resistant schizophrenia: Constructing a methylation risk score using a machine learning method.
Lu AK; Lin JJ; Tseng HH; Wang XY; Jang FL; Chen PS; Huang CC; Hsieh S; Lin SH
J Psychiatr Res; 2023 Jan; 157():57-65. PubMed ID: 36442407
[TBL] [Abstract][Full Text] [Related]
16. Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia.
Wimberley T; Gasse C; Meier SM; Agerbo E; MacCabe JH; Horsdal HT
Schizophr Bull; 2017 Sep; 43(5):1064-1069. PubMed ID: 28184875
[TBL] [Abstract][Full Text] [Related]
17. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.
Chan SKW; Chan HYV; Honer WG; Bastiampillai T; Suen YN; Yeung WS; Lam M; Lee WK; Ng RMK; Hui CLM; Chang WC; Lee EHM; Chen EYH
Schizophr Bull; 2021 Mar; 47(2):485-494. PubMed ID: 33043960
[TBL] [Abstract][Full Text] [Related]
19. Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study.
Yasui-Furukori N; Muraoka H; Hasegawa N; Ochi S; Numata S; Hori H; Hishimoto A; Onitsuka T; Ohi K; Hashimoto N; Nagasawa T; Takaesu Y; Inagaki T; Tagata H; Tsuboi T; Kubota C; Furihata R; Iga JI; Iida H; Miura K; Matsumoto J; Yamada H; Watanabe K; Inada K; Shimoda K; Hashimoto R
Neuropsychopharmacol Rep; 2022 Mar; 42(1):3-9. PubMed ID: 34854260
[TBL] [Abstract][Full Text] [Related]
20. Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.
Iasevoli F; Razzino E; Altavilla B; Avagliano C; Barone A; Ciccarelli M; D'Ambrosio L; Matrone M; Milandri F; Notar Francesco D; Fornaro M; de Bartolomeis A
Early Interv Psychiatry; 2022 Apr; 16(4):352-362. PubMed ID: 33998142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
